CSL's reset: impairments, Vifor headwinds, and a new growth narrative
FY26 results show a company resetting after a difficult year, with Vifor impairments and a pivot to NPAT as core metric.
CSL.AX · Earnings Call · 2026-08-17
A reset year
FY26 was, in Gordon Naylor's words, “a reset year for CSL” — Gordon Naylor, CEO · 2026-08-17. Revenue fell 1% to $15.8B on a constant-currency basis, and underlying NPAT dipped 3% to $2.8B. But the headline is the statutory loss of $2.6B, driven by $7.1B in pretax impairments, including a cost base write-down at Vifor of $4.1B. The company also shifted its primary profitability metric from NPATA to NPAT, a change that will make results simpler to track and aligns with how investors view the business.
Vifor's structural headwinds
Vifor's revenue grew 3% for the year, but the portfolio is facing severe generic competition in iron and the imminent loss of Velphoro's TDAPA reimbursement at year-end. The revocation of TAVNEOS's European marketing authorization added another blow. CFO Ken Lim explained that the impairment reflects “changing market dynamics, which Gordon has discussed, including increased generic competition, the conclusion of the TDAPA period for Velphoro and the revocation of the marketing authorization for TAVNEOS” — Ken Lim, CFO · 2026-08-17. For FY27, Vifor revenue is expected to drop ~25%, making it a material drag on group growth. The company is integrating Vifor's commercial and medical teams with Behring's to cut costs and reallocate resources, but the structural headwinds are not going away soon.
There are significant headwinds facing Vifor. These are structural and will materially affect the earnings profile of the business over FY '27.
Transformation and the path forward
The company delivered $176M in transformation savings in FY26, ahead of its $100M target. The program will deliver an incremental $220M in FY27, with annualized savings rising to $400M. Commercial initiatives are being selectively reinvested, particularly in the Behring franchise. Gordon Naylor told analysts; “The actions taken during FY '26 have reestablished the foundation. Our focus in FY '27 is to maintain momentum and demonstrate measurable progress.” — Gordon Naylor, CEO · 2026-08-17 This echoes the earlier sentiment from the February call, where Andy Schmeltz noted “The unmet need for Ig is significant and the diseases that Ig is used to treat primary and secondary immunodeficiency, CIDP, we see the diagnosis and the utilization of Ig growing, high single digits, low double digits.” — Andy Schmeltz, Executive · 2026-02-10 Ig remains the core growth engine, and the second-half improvement suggests the investments are gaining traction.
Horizon 2 and the pipeline
One notable change is the need for clinical studies for the Horizon 2 extraction technology, which had previously been expected to rely purely on comparability data. Ken Lim commented, “We remain very excited about Horizon 2 and the potential of that extraction technology to meaningfully increase the yields.” — Ken Lim, CFO · 2026-08-17 Construction at Kankakee has commenced, but the added clinical trials will push the timeline out. The Horizon 2 pilot is a key part of the company's long-term margin recovery story, and management remains committed to returning margins to historical highs, as Joy Linton reiterated last August: “We have not lost conviction at all on returning our margins to historical highs.” — Joy Carolyn Linton, Chief Financial Officer · 2025-08-19 The leadership transition also continues: Gordon Naylor, the interim CEO, is not a candidate for the permanent role, and the board's search is progressing. In the meantime, the company has authorized a further AUD 1.1B buyback and maintained its dividend, underscoring confidence in the underlying cash flow.